Home › Companies › OCGN

Ocugen

Market cap $257M 339.3M shares (10-Q, Oct 30, 2026) × $0.757 close Nov 17, 2026

Most recent annual filing: 2026-03-04

Catalyst timeline

6 trackedQuarter catalyst calendar →
  1. Proposal 1 vote FDA decisionDec 22, 2026Proposal 1 vote FDA decision, Dec 22, 2026, material
  2. Reserved Share Proposal corporate updateDec 22, 2026Reserved Share Proposal corporate update, Dec 22, 2026, routine
  3. Governance/Authorized Shares corporate updateDec 22, 2026Governance/Authorized Shares corporate update, Dec 22, 2026, routine
  4. Corporate governance / cap tableDec 22, 2026Corporate governance / cap table, Dec 22, 2026, routine
  5. OCU400 Ph3 topline1Q 2027OCU400 Ph3 topline, 1Q 2027, thesis-defining
  6. Bahamas early-access program corporate update~Jan 2027Bahamas early-access program corporate update, ~Jan 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (12 active programs)

Technology platforms

Novel Modifier Gene Therapy Platform · CanSino Biologics

Nuclear hormone receptor (NHR)-based modifier gene therapy platform using AAV5 vector delivery to retinal tissue; targets NR2E3 and RORA to address multiple inherited retinal diseases including retinitis pigmentosa, Stargardt disease, and dry AMD/geographic atrophy with a gene-agnostic approach

Targets: NR2E3, RORA

Inhaled Mucosal Vaccine Platform · Washington University in St. Louis

Next-generation inhalation-based mucosal vaccine platform based on a novel ChAd vector; designed to generate local mucosal immunity in the nasopharyngeal region for respiratory infectious diseases including COVID-19 and influenza

Targets: SARS-CoV-2 Spike protein, influenza

modifier gene therapy platform

Gene-agnostic modifier gene therapy platform designed to address underlying disease biology and restore balance across multiple gene networks, enabling treatment of large patient populations with inherited retinal diseases and other causes of blindness including retinitis pigmentosa, Stargardt disease, and geographic atrophy/dry AMD

Targets: NR2E3

Inhaled Mucosal Vaccine Platform · National Institute of Allergy and Infectious Diseases

Next-generation inhaled mucosal vaccine platform; focus area: infectious diseases including COVID-19

Capital (as filed)

Cash
$24.6M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$59.6M Sep 30, 2026
Operating cash flow
−$15.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$84.6M cash, runway 2028 per the update of Nov 4, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (18)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (18 calls)

Every verdict Biotech Distilled has published on Ocugen, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Ocugen inc. (OCGN): Scientific Deep Dive for OCU400 and Pipeline Products High-conviction science shackled to a distressed balance sheet; most investors should wait for a capital raise and dilution overhang to clear before entering.
  2. Speculative buy speculative CORRECTION & UPDATE: Ocugen (OCGN) Pays the Piper Clean $22.5M common stock raise with no warrants removes immediate bankruptcy risk and warrant overhang, improving risk/reward for aggressive traders playing near-term data catalysts.
  3. Speculative buy speculative UPDATE: Ocugen (OCGN) – 2025 Fiscal Year Update Clinical thesis intact with imminent Phase 2 GA data as a major binary catalyst, but Delaware Chancery Court cap-table chaos is a severe distraction until the May 6 hearing resolves.
  4. Speculative buy speculative UPDATE: Ocugen (OCGN) – The Smart Money Shrugs Off the Delaware Drama Institutional warrant exercise of $15M mid-Delaware-chaos signals the legal issue is a formality, extends runway into Q1 2027, and refocuses attention on imminent clinical readouts.
  5. Speculative buy speculative UPDATE: Ocugen (OCGN) - Phase 2 GA Data Drops – The Receipts Are In Full Phase 2 OCU410 data showing 31% lesion reduction with clean safety profile profoundly de-risks the science thesis, making OCU410 a premier M&A target, though Delaware legal overhang persists until May.
  6. Speculative buy speculative UPDATE: Ocugen (OCGN) – The Reverse Split Cometh Clinical thesis compounding on every shot on goal while governance shadow grows; smart money signals (Millennium 5.2%, RTW, Janus Henderson) confirm conviction ahead of May 6 Delaware ruling and June 11 annual meeting.
  7. Speculative buy speculative UPDATE: Ocugen (OCGN) – The Fortress Gets Built (On Borrowed Bricks) $115M+ convertible offering kills Avenue debt and extends runway plausibly into 2028, transforming the distressed balance sheet into a genuine fortress while science continues to compound.
  8. Speculative buy speculative UPDATE: Ocugen (OCGN) – The Convert Prices, The Arb Sells, The Stock Bleeds The 19.5% stock drop on convertible pricing is mechanical arb-driven selling, not fundamental repricing; financing risk is now bounded and the science is unchanged, making the drawdown a potential entry point.
  9. Speculative buy speculative UPDATE: Ocugen (OCGN) – The Greenshoe Gets Pulled, The CMO Walks Full $130M greenshoe exercise confirms institutional conviction while abrupt CMO departure two months before rolling BLA initiation adds a new governance question that warrants monitoring but not panic.
  10. Speculative buy speculative UPDATE: Ocugen (OCGN) – The Annual Meeting That Didn't Mention the Reverse Split Genead made permanent CMO closes one open question, but the conspicuous absence of Proposal 5 (reverse split) results leaves the convertible's stock-settlement mechanics and CEO comp penalty unresolved.
  11. Speculative buy speculative UPDATE: Ocugen (OCGN) – The Second Regional Deal Lands MENA regional OCU400 deal with 22% royalty and supply contract confirms the partnership playbook is working and negotiating leverage has improved post-convertible, while Proposal 5 silence now a month old.
  12. Speculative buy speculative UPDATE: Ocugen (OCGN) – RMAT Lands, BlackRock Shows Up, Stock Doesn't Care FDA RMAT designation for OCU410 independently validates the Phase 2 clinical signal and accelerates the regulatory path, while BlackRock's 8% stake is the sixth smart-money signal, though Proposal 5 silence now 48 days old remains the key overhang.
  13. Speculative buy speculative UPDATE: Ocugen (OCGN) – The Rolling BLA Rolls Away Delaware legally resolved and September 21 reserved-share vote date finally announced, but OCU400 rolling BLA reframed to post-Phase 3 topline, removing the key Q3 de-risking waypoint and extending the data gap to Q1 2027.
  14. Speculative buy speculative UPDATE: Ocugen (OCGN) – First Patient Dosed in ArMaDa3 ArMaDa3 Phase 3 first patient dosed on schedule confirms operational execution, but September 21 reserved-share vote remains the gating structural event before the Q1 2027 binary readout.
  15. Watch UPDATE: Ocugen (OCGN) - The Unlock Gets Postponed September 21 reserved-share vote adjourned without passing, stock sitting on Nasdaq's $1.00 minimum bid, and management has now failed twice to close a needed shareholder vote, warranting a downgrade to Watch until October 5 resolves the issue.
  16. Watch UPDATE: Ocugen (OCGN) - Adjourned Again Second adjournment of the authorized-share vote with the same electorate that couldn't pass it, while the December 31 CEO penalty deadline draws closer; October 26 is now the deciding event.
  17. Avoid UPDATE: Ocugen (OCGN) - The Vote Slips to December Third delay of the authorized-share vote to December 22 — nine days before the CEO cash-settlement deadline — combined with stock falling below Nasdaq's $1.00 minimum bid triggers the explicit downgrade condition set on October 6.
  18. Avoid UPDATE: Ocugen (OCGN) - The Loss That Shrank Because the Stock Fell Q3 confirms September vote failed outright, revived class action adds litigation risk, and the headline net loss improvement is an accounting artifact of the stock falling; December 22 vote remains the only gate for reversing the stance.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (6 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (52)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 13, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)